RTW INVESTMENTS, LPRTW INVESTMENTS, LP

Institutional investor · Portfolio as of Q2 2022

SEC EDGAR SourceSEC Filings

Top Holdings107 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction

ALNYLAM PHARMACEUTICALS INC

1.7M$245.5M6.3%$94.58+53.76%
14 qtrssince 2019-Q1
Unchanged
0

THERMO FISHER SCIENTIFIC INC

435,500$236.6M6.1%$570.15-6.94%
4 qtrssince 2021-Q3
Increased
69

ROCKET PHARMACEUTICALS INC

15.8M$217.4M5.6%$18.70-30.32%
14 qtrssince 2019-Q1
Unchanged
0

PTC THERAPEUTICS INC

5M$202.1M5.2%$41.64-2.98%
14 qtrssince 2019-Q1
Decreased
0
MASIMASIDelisted

MASIMO CORP

1.4M$176.5M4.6%$177.58-23.35%
14 qtrssince 2019-Q1
Increased
66
ARGXARGX
ADR

ARGENX SE - ADR

442,635$167.7M4.3%$327.56+15.67%
14 qtrssince 2019-Q1
Increased
71
IMCRIMCR
ADR

IMMUNOCORE HLDGS PLC

4M$149.1M3.9%$37.22-3.55%
6 qtrssince 2021-Q1
Increased
90

ESTABLISHMENT LABS HLDGS INC

2.4M$128.8M3.3%$22.63+149.35%
14 qtrssince 2019-Q1
Increased
56
MRTXMRTXDelisted

MIRATI THERAPEUTICS INC

1.9M$126.4M3.3%
14 qtrssince 2019-Q1
Increased
66

ILLUMINA INC

564,375$104M2.7%$320.70-43.45%
8 qtrssince 2020-Q3
Increased
57

CYTOKINETICS INC

2.6M$100.6M2.6%$26.89+46.10%
8 qtrssince 2020-Q3
Unchanged
0
RXDXRXDXDelisted

PROMETHEUS BIOSCIENCES INC

3.2M$90M2.3%
6 qtrssince 2021-Q1
Increased
59

VERICEL CORP

3.5M$88.7M2.3%$17.25+46.82%
14 qtrssince 2019-Q1
Decreased
0

PENUMBRA INC

698,371$87M2.2%$262.94-50.46%
4 qtrssince 2021-Q3
Increased
54

Celldex Therapeutics, Inc.

3.1M$83.2M2.1%$14.23+95.53%
9 qtrssince 2020-Q2
Unchanged
0

Ultragenyx Pharmaceutical, Inc.

1.4M$81.9M2.1%$84.25-28.50%
3 qtrssince 2021-Q4
Unchanged
0

NATERA INC

2.1M$75.2M1.9%$42.33-12.90%
12 qtrssince 2019-Q3
Increased
52
4.8M$69.7M1.8%$26.39-45.81%
9 qtrssince 2020-Q2
Unchanged
0
AXNXAXNXDelisted

AXONICS INC

1.2M$66.9M1.7%
14 qtrssince 2019-Q1
Decreased
0
CUTRQCUTRQDelisted

CUTERA INC

1.8M$66.4M1.7%
5 qtrssince 2021-Q2
Increased
54
$3.9B
AUM
107
Positions
Q2 2022
Filing
Rating · 4.5
Quarterly Portfolio Change
+7%Q1'21$6.4B+3%Q2'21$6.6B+0%Q3'21$6.6B+3%Q4'21$6.8B-29%Q1'22$4.8B-20%Q2'22$3.9B
Activity profile
$ moved · Q2'22
New12%Increased52%Decreased30%Exited5%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 1.5 years
<1Q8%1-4Q25%1-2Y34%2Y+33%

RTW INVESTMENTS, LP manages $3.9B across 107 positions as of Q2 2022. Top holdings: ALNY (6.3%), TMO (6.1%), RCKT (5.6%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 4.5/5.0.

Q2 2022 Summary

Active quarter - 10 new positions, 9 exits, 28 increased. Top move: IMCR (INCREASED, conviction 90). Portfolio: $3.9B across 107 positions.

Top holdings by portfolio weight

Total AUM$4B
ALNY6.34%
TMO6.11%
RCKT5.62%
PTCT5.22%
MASI4.56%
ARGX4.33%
IMCR3.85%
ESTA3.33%
MRTX3.27%
ILMN2.69%
Other2.60%

Portfolio allocation by GICS sector

Sectors3
Healthcare83.75%
Unknown15.98%
Industrials0.27%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare, Unknown
Compare DNA across all funds
7-dimension quality assessment
Elite(4.5 / 5.0)
Track Record61
Conviction45
Concentration72
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
7Q
RDNTRDNTRadNet, Inc.
Q4 2024 Q2 2026+3M shares+$173.4M
6Q
CMPSCMPSCOMPASS PATHWAYS PLC
Q1 2025 Q2 2026+7.6M shares+$139.7M
6Q
IMTXIMTXIMMATICS N.V
Q1 2025 Q2 2026+6.4M shares+$84.6M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used